GT BIOPHARMA, INC. Form D Notices of Exempt Offering of Securities
Notices filed with the SEC for securities sold without registration under Regulation D or Section 4(a)(5), newest first. Values are as filed.
- 2025-05-27: Federal exemption Rule 506(b); Types of securities offered Equity; OptionToAcquire; SecurityToBeAcquired; Date of first sale 2025-05-12; Total offering amount $5,950,000.
- 2025-03-07: Federal exemption Rule 506(b); Types of securities offered Equity; OptionToAcquire; SecurityToBeAcquired; Date of first sale 2025-02-25; Total offering amount $1,280,358.
- 2020-07-23: Federal exemption Rule 506(b); Types of securities offered Debt; Debt convertible into equity.; Date of first sale 2020-04-20; Total offering amount Indefinite.
- 2020-06-12: Federal exemption Rule 506(b); Types of securities offered Debt; Debt convertible into equity; Date of first sale 2020-04-20; Total offering amount Indefinite.
| Filed | Federal exemption | Types of securities offered | Date of first sale | Total offering amount | Total amount sold | Total remaining to be sold | Investors who have already invested |
|---|---|---|---|---|---|---|---|
| 2025-05-27 | Rule 506(b) | Equity; OptionToAcquire; SecurityToBeAcquired | 2025-05-12 | $5,950,000 | $5,950,000 | $0 | 9 |
| 2025-03-07 | Rule 506(b) | Equity; OptionToAcquire; SecurityToBeAcquired | 2025-02-25 | $1,280,358 | $1,280,358 | $0 | 6 |
| 2020-07-23 D/A | Rule 506(b) | Debt; Debt convertible into equity. | 2020-04-20 | Indefinite | $5,607,000 | Indefinite | 18 |
| 2020-06-12 | Rule 506(b) | Debt; Debt convertible into equity | 2020-04-20 | Indefinite | $2,417,000 | Indefinite | 9 |
| 2018-02-06 | Rule 506(b) | Debt; OptionToAcquire | 2018-01-23 | $7,055,000 | $7,055,000 | $0 | 14 |
| 2017-09-14 | Rule 506(b) | Equity; Debt | 2016-08-31 | $4,540,000 | $4,540,000 | $0 | 9 |
| 2015-07-27 | Rule 506(b) | Equity; Debt | 2015-07-09 | $1,500,000 | $500,000 | $1,000,000 | 2 |
| 2015-03-16 | Rule 506(b) | Equity; Debt | 2015-02-20 | $3,000,000 | $2,050,000 | $950,000 | 7 |
| 2014-07-31 | Rule 506(b) | Debt; OptionToAcquire | 2014-07-24 | $1,425,000 | $1,425,000 | $0 | 11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |